Synexus Expands in Germany with New Center in Bochum - Applied Clinical Trials

ADVERTISEMENT

See our 2013 Buyers Guide Digital Edition.
Synexus Expands in Germany with New Center in Bochum

Source: Applied Clinical Trials

Synexus has opened a research center in Bochum, which is the company’s fourth in Germany and its 23rd in total. The clinic has moved from a much smaller site in Bochum and is situated in the historic Kortum House. The five hundred square meter clinic runs primary care clinical trials for major clinical research organizations and pharmaceutical companies and provides facilities for up to six professional investigators.

“Germany is one of our foremost locations for running clinical trials with its excellent medical expertise, a history of running clinical trials and a large population,” said Christophe Berthoux, CEO of Synexus. “Europe continues to be a favored region for our clients in the running of their global clinical trials and we are planning to further develop our business in Germany.”

The new clinic, which will be managed by Annette Kuehlenborg, is well placed for easy patient access because it is close to the main station and has parking facilities in the immediate vicinity. The company’s other German centers are in Frankfurt, Berlin, and Leipzig.

“This is a further step in our plan to update and expand our very successful network of clinics across Germany by providing modern clinics which benefit both our patients and our clients in pharma,” noted German Managing Director Christoph Dietrich. “Our success in bringing clinical trials to Germany is dependent on our ability to deliver patients and quality data. We have now put in place a sophisticated patient engagement program which improves the patient experience and it is these added-value extras which really pay dividends in terms of client success.”

All of Synexus’ 26 clinics across Europe and Africa focus particularly on undertaking cardiovascular, metabolic (diabetes and obesity), musculoskeletal, respiratory and central nervous system (dementia and pain) trials.

Read the full release here.

ADVERTISEMENT

blog comments powered by Disqus

ADVERTISEMENT

Survey
As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
86%
Borrow lightly from EMA's pathway program?
6%
Create entirely its own pathway program?
7%
View Results
Untitled Document
Source: Applied Clinical Trials,
Click here